Extraordinary General Meeting in Oncopeptides AB (publ) – Nov 03, 2020
The Pharma Data
NOVEMBER 2, 2020
Melflufen (INN melphalan flufenamide) is in development as a new treatment for the hematological malignancy multiple myeloma and is currently being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides’ global Headquarters is in Stockholm, Sweden and the U.S.
Let's personalize your content